Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
GRAL Stock Forecast 2026-2027
$51.71
Current Price
$2.12B
Market Cap
Buy 4
Hold 4
Sell 0
Wall St Analyst Ratings
Distance to GRAL Price Targets
+58.6%
To High Target of $82.00
+25.7%
To Median Target of $65.00
+4.4%
To Low Target of $54.00
GRAL Price Momentum
+7.6%
1 Week Change
+10.4%
1 Month Change
+91.5%
1 Year Change
-39.6%
Year-to-Date Change
-56.5%
From 52W High of $118.84
+102.3%
From 52W Low of $25.56
📊 TOP ANALYST CALLS
Did GRAL Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if GRAIL, Inc. is one of their latest high-conviction picks.
Latest GRAL Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, GRAL has a neutral consensus with a median price target of $65.00 (ranging from $54.00 to $82.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $51.71, the median forecast implies a 25.7% upside. This outlook is supported by 4 Buy, 4 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Catherine Schulte at Baird, projecting a 58.6% upside. Conversely, the most conservative target is provided by David Westenberg at Piper Sandler, suggesting a 4.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
GRAL Analyst Ratings
4
Buy
4
Hold
0
Sell
GRAL Price Target Range
Low
$54.00
Average
$65.00
High
$82.00
Current: $51.71
Latest GRAL Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for GRAL.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Piper Sandler | David Westenberg | Neutral | Initiates | $54.00 |
| Apr 10, 2026 | Mizuho | Bradley Bowers | Neutral | Initiates | $58.00 |
| Mar 30, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $75.00 |
| Feb 24, 2026 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $60.00 |
| Feb 20, 2026 | Baird | Catherine Schulte | Outperform | Maintains | $82.00 |
| Feb 20, 2026 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $80.00 |
| Feb 17, 2026 | Baird | Catherine Schulte | Outperform | Initiates | $113.00 |
| Jan 26, 2026 | Guggenheim | Subbu Nambi | Buy | Maintains | $130.00 |
| Dec 2, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $110.00 |
| Nov 17, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $105.00 |
| Nov 12, 2025 | Guggenheim | Subbu Nambi | Buy | Upgrade | $100.00 |
| Oct 22, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $85.00 |
| Oct 3, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $75.00 |
| May 14, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $43.00 |
| Apr 21, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Initiates | $32.00 |
| Mar 18, 2025 | Morgan Stanley | Tejas Savant | Equal-Weight | Maintains | $20.00 |
| Nov 27, 2024 | Morgan Stanley | Tejas Savant | Equal-Weight | Initiates | $16.00 |
| Oct 17, 2024 | Guggenheim | Subbu Nambi | Neutral | Initiates | $N/A |
Grail, Inc. (GRAL) Competitors
The following stocks are similar to GRAIL, Inc. based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Grail, Inc. (GRAL) Financial Data
Grail, Inc. has a market capitalization of $2.12B with a P/E ratio of -4.6x. The company generates $147.17M in trailing twelve-month revenue with a -277.5% profit margin.
Revenue growth is +14.0% quarter-over-quarter, while maintaining an operating margin of -285.4% and return on equity of -16.1%.
Valuation Metrics
Market Cap
$2.12B
Enterprise Value
$1.27B
P/E Ratio
-4.6x
PEG Ratio
0.3x
Price/Sales
14.4x
Growth & Margins
Revenue Growth (YoY)
+14.0%
Gross Margin
-25.5%
Operating Margin
-285.4%
Net Margin
-277.5%
EPS Growth
+14.0%
Financial Health
Cash/Price Ratio
+42.6%
Current Ratio
12.0x
Debt/Equity
2.1x
ROE
-16.1%
ROA
-11.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Grail, Inc. (GRAL) Business Model
About Grail, Inc.
What They Do
Develops multi-cancer early detection technologies.
Business Model
Grail, Inc. generates revenue by offering its flagship Galleri test, a blood-based liquid biopsy that screens for multiple types of cancer. The company conducts large-scale clinical trials to validate its technologies and collaborates with healthcare providers and institutions to enhance its product offerings and expand market reach.
Additional Information
Founded in 2015 and headquartered in Menlo Park, California, Grail utilizes advanced technologies like next-generation sequencing and machine learning to improve cancer detection. The company is actively involved in significant clinical studies such as the NHS-Galleri trial, aimed at refining its tests and contributing to better healthcare outcomes globally.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
910
CEO
Mr. Robert P. Ragusa
Country
United States
IPO Year
2024
Website
grail.comGrail, Inc. (GRAL) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
GRAIL Partners With Epic to Broaden Galleri Test Access Across US
GRAIL partners with Epic to embed its Galleri cancer test into EHRs, expanding access across nearly 450 health systems and streamlining clinical workflows nationwide.
Apr 08, 2026
By Zacks Equity Research
Analyst Blog
Latest News
GRAL DROPS ~50% -- REPORTED NUMBERS VS. ACTUAL RESULTS; LEVI & KORSINSKY, LLP INVESTIGATES
5 days ago
Quick Summary
Grail, Inc. (NASDAQ: GRAL) shares fell about 50% after the NHS Galleri trial missed its primary endpoint, leading to significant investor losses and concerns over cash burn projections.
Why It Matters
Grail's significant cash burn and missed trial milestones raise concerns about financial stability and future performance, likely influencing investor sentiment and stock valuation negatively.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
GRAIL, Inc. (NASDAQ: GRAL) shares experienced an increase in the premarket session on Wednesday.
Why It Matters
GRAIL, Inc.'s premarket share increase may indicate positive market sentiment, potentially attracting further investment and influencing stock performance throughout the trading day.
Source: Benzinga
Market Sentiment:
Positive
Quick Summary
GRAIL partners with Epic to integrate its Galleri cancer test into EHRs, enhancing access in nearly 450 health systems and improving clinical workflows across the U.S.
Why It Matters
GRAIL's partnership with Epic enhances Galleri's market reach and integration in healthcare systems, potentially increasing revenue and adoption rates, positively impacting investor sentiment.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
GRAIL's NHS-Galleri trial results have been described as disappointing rather than a complete failure, indicating potential challenges for the company's future.
Why It Matters
GRAIL’s trial results may impact its market potential and investor confidence, influencing stock performance and the biotech sector's outlook.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
GRAIL, Inc. announced a collaboration with Epic to integrate the Galleri multi-cancer early detection test into EHR systems, enabling 450 health systems to access results and order tests easily.
Why It Matters
GRAIL's collaboration with Epic enhances the accessibility of its cancer detection test, potentially increasing adoption rates and revenue, positively impacting investor sentiment and stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
GRAL Investors Have Opportunity to Join GRAIL, Inc. Fraud Investigation with the Schall Law Firm
16 days ago
Quick Summary
GRAIL, Inc. is under investigation for fraud, and GRAL investors can join the inquiry led by the Schall Law Firm.
Why It Matters
The investigation into GRAIL, Inc. may signal potential legal and financial risks for $GRAL investors, impacting stock valuation and future performance.
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About GRAL Stock
What is Grail, Inc.'s (GRAL) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Grail, Inc. (GRAL) has a median price target of $65.00. The highest price target is $82.00 and the lowest is $54.00.
Is GRAL stock a good investment in 2026?
According to current analyst ratings, GRAL has 4 Buy ratings, 4 Hold ratings, and 0 Sell ratings. The stock is currently trading at $51.71. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for GRAL stock?
Wall Street analysts predict GRAL stock could reach $65.00 in the next 12 months. This represents a 25.7% increase from the current price of $51.71. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Grail, Inc.'s business model?
Grail, Inc. generates revenue by offering its flagship Galleri test, a blood-based liquid biopsy that screens for multiple types of cancer. The company conducts large-scale clinical trials to validate its technologies and collaborates with healthcare providers and institutions to enhance its product offerings and expand market reach.
What is the highest forecasted price for GRAL Grail, Inc.?
The highest price target for GRAL is $82.00 from Catherine Schulte at Baird, which represents a 58.6% increase from the current price of $51.71.
What is the lowest forecasted price for GRAL Grail, Inc.?
The lowest price target for GRAL is $54.00 from David Westenberg at Piper Sandler, which represents a 4.4% increase from the current price of $51.71.
What is the overall GRAL consensus from analysts for Grail, Inc.?
The overall analyst consensus for GRAL is neutral. Out of 6 Wall Street analysts, 4 rate it as Buy, 4 as Hold, and 0 as Sell, with a median price target of $65.00.
How accurate are GRAL stock price projections?
Stock price projections, including those for Grail, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:01 AM UTC